Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.

Laan W, Grobbee DE, Selten JP, Heijnen CJ, Kahn RS, Burger H.

J Clin Psychiatry. 2010 May;71(5):520-7. doi: 10.4088/JCP.09m05117yel.

PMID:
20492850
[PubMed - indexed for MEDLINE]
2.

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.

Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B.

Schizophr Res. 2007 Feb;90(1-3):179-85. Epub 2007 Jan 8.

PMID:
17208413
[PubMed - indexed for MEDLINE]
4.

Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.

Akhondzadeh S, Safarcherati A, Amini H.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):253-9. Epub 2004 Dec 28.

PMID:
15694232
[PubMed - indexed for MEDLINE]
5.

Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis.

Sommer IE, de Witte L, Begemann M, Kahn RS.

J Clin Psychiatry. 2012 Apr;73(4):414-9. doi: 10.4088/JCP.10r06823. Epub 2011 Dec 13.

PMID:
22225599
[PubMed - indexed for MEDLINE]
6.
7.

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.

Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.

Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.

PMID:
16275807
[PubMed - indexed for MEDLINE]
8.

Celecoxib augmentation of continuously ill patients with schizophrenia.

Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D.

Biol Psychiatry. 2005 Jun 15;57(12):1594-6.

PMID:
15953498
[PubMed - indexed for MEDLINE]
9.

Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia.

Na KS, Kim YK.

Neuropsychobiology. 2007;56(2-3):55-63. Epub 2007 Nov 23.

PMID:
18037815
[PubMed - indexed for MEDLINE]
10.

Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.

Patrick DL, Burns T, Morosini P, Gagnon DD, Rothman M, Adriaenssen I.

Clin Ther. 2010 Feb;32(2):275-92. doi: 10.1016/j.clinthera.2010.02.003.

PMID:
20206786
[PubMed - indexed for MEDLINE]
11.

Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.

Möller HJ, Riedel M, Müller N, Fischer W, Kohnen R.

Pharmacopsychiatry. 2004 Nov;37(6):270-8.

PMID:
15551193
[PubMed - indexed for MEDLINE]
12.

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.

Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ.

Am J Psychiatry. 2002 Jun;159(6):1029-34.

PMID:
12042193
[PubMed - indexed for MEDLINE]
13.

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.

Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Hajiazim M, Raznahan M, Akhondzadeh S.

Hum Psychopharmacol. 2008 Mar;23(2):79-86.

PMID:
17972359
[PubMed - indexed for MEDLINE]
14.

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.

Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG.

Arch Gen Psychiatry. 1997 Jun;54(6):549-57.

PMID:
9193196
[PubMed - indexed for MEDLINE]
15.

Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial.

Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, Malloy H, Rowland C, Monkhouse A, Monkhouse A, Bole F, Sathiyamoorthy S, Piskulic D, Dodd S.

Hum Psychopharmacol. 2009 Apr;24(3):233-8. doi: 10.1002/hup.1017.

PMID:
19330802
[PubMed - indexed for MEDLINE]
16.

Th1, Th2 and Th3 cytokine alteration in schizophrenia.

Kim YK, Myint AM, Lee BH, Han CS, Lee HJ, Kim DJ, Leonard BE.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1129-34.

PMID:
15610925
[PubMed - indexed for MEDLINE]
17.

Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.

Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ.

Am J Psychiatry. 2002 Sep;159(9):1596-8.

PMID:
12202284
[PubMed - indexed for MEDLINE]
18.

The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.

Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y.

CNS Drugs. 2009;23(7):615-25. doi: 10.2165/00023210-200923070-00006.

PMID:
19552488
[PubMed - indexed for MEDLINE]
19.

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.

Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA.

Am J Psychiatry. 2005 Jan;162(1):130-6.

PMID:
15625211
[PubMed - indexed for MEDLINE]
20.

Diazoxide in the treatment of schizophrenia: novel application of potassium channel openers in the treatment of schizophrenia.

Akhondzadeh S, Mojtahedzadeh V, Mirsepassi GR, Moin M, Amini-Nooshabadi H, Kamalipour A.

J Clin Pharm Ther. 2002 Dec;27(6):453-9.

PMID:
12472985
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk